TOVX: Bathi resik saben saham (EPS TTM) Synthetic Biologics

Theriva Biologics, Inc. (TOVX) business relies on Phase 2/3 test results and the fight against infections in cancer patients, as illustrated by the 12-month EPS trend, where the indicator level stands at -0.25. A stable staff of leading oncologists and biotech experts minimizes talent attrition in R&D. However, the lack of commercial products and a small market capitalization create high stock volatility.
Ringkesan rincian data analitis Theriva Corp (TOVX)

This indicator reflects the actual profit share per common share over a rolling year. By analyzing the net income per share over a 12-month period, an investor sees the final financial result net of all expenses. The metric is sensitive to changes in the number of securities and the volume of net income. For Theriva Biologics, Inc. (TOVX), this is critical due to the massive costs of clinical trials. Should the patents succeed, the low cost of therapy will ensure a sharp spike in this metric.